We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bayer Submits Pulmonary Hypertension Drug for U.S., EU Approval
Bayer Submits Pulmonary Hypertension Drug for U.S., EU Approval
February 11, 2013
Bayer HealthCare has submitted its oral drug riociguat to treat inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) for approval in the U.S. and EU.